- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Genetic testing based on whole-genome sequencing (WGS) often returns results that are not directly clinically actionable as well as raising the possibility of incidental (secondary)
findings. In this article, we first survey the laws and policies guiding both researchers and clinicians in the return of results for WGS-based genetic testing. We then provide an overview
of the landscape of international legislation and policies for return of these results, including considerations for return of incidental findings. Finally, we consider a range of approaches
for the return of results.
The authors thank E. Kleiderman and A. Pack (from the Centre of Genomics and Policy) for their assistance. In addition, the authors thank the Ministère de l'Économie, l'Innovation et des
Exportations du Québec; the Fonds de Recherche du Québec; the Network of Applied Genetic Medicine of Québec; and Care4Rare Canada Consortium funded by Genome Canada, the Canadian Institutes
of Health Research, the Ontario Genomics Institute, Ontario Research Fund, Genome Quebec and Children's Hospital of Eastern Ontario Foundation.
Department of Human Genetics, Centre of Genomics and Policy, Faculty of Medicine, McGill University, 740, avenue Dr. Penfield, Montréal, H3A 0G1, Quebec, Canada, Canada
Anyone you share the following link with will be able to read this content:
